Episode Player

Send us Fan Mail

Six times lower capture antibody usage and faster activation sounds like a marketing claim until you unpack what it does to cost, workflow, and test performance. We sit down with Merrill Gray, Managing Director and CEO of AnteoTech Limited (ASX: ADO), to explain how AnteoTech’s chemical and materials science platform improves molecule-to-surface bonding and why that matters in modern immunoassays and precision diagnostics.

We walk through AnteoTech’s move into CLIA diagnostics, including the successful completion of an initial stage in a collaborative CLIA development program with a large global life sciences company and the next stage already agreed. Merrill breaks down the practical value of superior antibody orientation on magnetic beads, and why reproducibility and sensitivity are the difference between a promising chemistry and a deployable in vitro diagnostics solution. We also discuss the upcoming ADLM 2026 launch of a ready-to-use CLIA kit that bundles magnetic beads, AnteoBind™ NXT , and optimised activation protocols, plus what “moving up the value chain” looks like when your customers range from vaccine R&D teams to pathology and research labs.

Then we pivot to advanced battery technology, where the same platform shows up as performance additives and materials choices that target real manufacturing constraints. You’ll hear how Anteo C progressed from 100 mL lab work to a 20-litre sample shipped for manufacturing scale trials in South Korea, why primer coatings on copper foil and aluminium foil matter for electrode performance, and how separator integrity links to safety and thermal runaway risk. We close on what to watch over the next six months, including regional go-to-market choices and progress on Ultranode™  high-silicon anode work aimed at high-power battery packs. If you find value here, subscribe, share the episode, and leave a review so more investors and builders can discover it.